Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation

详细信息    查看全文

• 作者：Ting Zhang ; Songlei Zhou ; Ling Hu ; Bo Peng ; Yang Liu ; Xiang Luo ; Yanzhi Song ; Xinrong Liu ; Yihui Deng ; ^{pharmdeng@gmail.com}
• 关键词：AUC(0-t) ; area under the drug concentration-time curve values ; Cmax ; maximum concentration ; CLz ; total clearance ; DiR ; 1 ; 1&prime ; -dioctadecyl-3 ; 3 ; 3&prime ; 3&prime ; -tetramethyl indotricarbocyanine iodide ; DiR-CL ; DiR-labeled common liposomes ; DiR-SL ; DiR-labeled PSA-BS18 modified liposomes ; DiR-PL ; DiR-labeled mPEG2000-DSPE modified liposomes ; EE ; encapsulation efficiency ; EPI ; epirubicin ; EPI-S ; EPI solution ; EPI-CL ; common liposomal EPI ; EPI-SL ; PSA-BS18 modified liposomal EPI ; EPI-PL ; mPEG2000
• 刊名：International Journal of Pharmaceutics
• 出版年：2016
• 出版时间：30 December 2016
• 年：2016
• 卷：515
• 期：1-2
• 页码：449-459
• 全文大小：2662 K
• 卷排序：515

文摘

A new PSA derivative, polysialic acid-octadecyl dimethyl betaine conjugate (PSA-BS18), was synthesized. PSA-BS18 modified epirubicin liposomes were successfully prepared and characterized. PSA-BS18 is a suitable material to prolong the circulation time of the modified liposomes. In vivo studies confirmed EPI-SL have enhanced tumor accumulation and improved antitumor efficacy.